Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients
- PMID: 38198511
- PMCID: PMC11058023
- DOI: 10.1002/cncr.35189
Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients
Abstract
Background: The Center for International Blood and Marrow Transplant Research (CIBMTR) provides a 1-year overall survival calculator to estimate outcomes for individual patients before they undergo allogeneic hematopoietic cell transplantation (HCT) to inform risk. The calculator considers pre-HCT clinical and demographic characteristics, but not patient-reported outcomes (PROs). Because pre-HCT PRO scores have been associated with post-HCT outcomes, the authors hypothesized that adding PRO scores to the calculator would enhance its predictive power.
Methods: Clinical data were obtained from the CIBMTR and the Blood and Marrow Transplant Clinical Trials Network. The PRO measures used were the 36-Item Short Form Survey (SF-36) and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation. One thousand thirty-three adult patients were included.
Results: When adjusted for clinical characteristics, the SF-36 physical component score was significantly predictive of 1-year survival (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.81-0.95; p = .0015), whereas the mental component score was not (HR, 1.02; 95% CI, 0.95-1.10; p = 0.6396). The baseline single general health question on the SF-36 was also significantly associated with mortality (HR, 1.91 for those reporting fair/poor health vs. good, very good, or excellent health; 95% CI, 1.33-2.76; p = .0005). The addition of PRO scores to the calculator did not result in a significant change in the model's predictive ability. Self-reported pre-HCT scores were strongly predictive of self-reported health status (odds ratio, 3.35; 95% CI, 1.66-6.75; p = .0007) and quality of life (odds ratio, 3.24; 95% CI, 1.93-5.41; p < .0001) after HCT.
Conclusions: The authors confirmed the significant, independent association of pre-HCT PRO scores with overall survival, although adding PRO scores to the survival calculator did not improve its performance. They also demonstrated that a single general health question was as accurate as the full measure for predicting survival, an important finding that may reduce respondent burden and promote its inclusion in routine clinical practice. Validation of these findings should be performed.
Keywords: hematopoietic cell transplantation (HCT); patient‐reported outcome (PRO); single‐item health question; tools.
© 2024 American Cancer Society.
Conflict of interest statement
Dr. Shaw reports OrcaBio and Mallinkrodt.
Dr. Flynn reports research funding compensation to her institution from Novartis.
Dr. D’Souza reports Institutional research funding: Abbvie, Caelum, Janssen, Novartis, Prothena, Sorrento, Takeda, TeneoBio Ad Board/Consulting- BMS, Pfizer, Janssen, Prothena.
Dr. Hamilton reports compensation from Nkarta ad hoc advisory board; Angiocrine data safety monitoring committee; Therakos/Mallinkrodt speaker fees; Kadmon/Sanofi ad hoc advisory board; Incyte consultancy; Equilium ad hoc advisory board.
Dr. Phelan reports institutional research funding from Amgen and advisory board fees from bluebird bio.
Dr. Lee reports compensation from research funding: Amgen, AstraZeneca, Incyte, Kadmon, Pfizer, Syndax; Steering committee: Incyte; Drug supply: Janssen; Consulting: Mallinckrodt, Equillium, Kadmon.
Figures
Similar articles
-
Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.Cancer. 2017 Dec 1;123(23):4687-4700. doi: 10.1002/cncr.30936. Epub 2017 Aug 17. Cancer. 2017. PMID: 28817182 Free PMC article.
-
Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).Cancer. 2016 Jan 1;122(1):91-8. doi: 10.1002/cncr.29717. Epub 2015 Oct 6. Cancer. 2016. PMID: 26439325 Free PMC article. Clinical Trial.
-
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. doi: 10.1016/j.bbmt.2015.04.004. Epub 2015 Apr 7. Biol Blood Marrow Transplant. 2015. PMID: 25862591 Free PMC article.
-
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.Cancer. 2021 Feb 15;127(4):609-618. doi: 10.1002/cncr.33232. Epub 2020 Oct 21. Cancer. 2021. PMID: 33085090 Free PMC article.
-
Comparing Hematopoietic Cell Transplant versus Other Treatments for Adults with Acute Myeloid Leukemia [Internet].Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Jan. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Jan. PMID: 38232198 Free Books & Documents. Review.
Cited by
-
Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.Transplant Cell Ther. 2025 Jul 1:S2666-6367(25)01284-9. doi: 10.1016/j.jtct.2025.06.030. Online ahead of print. Transplant Cell Ther. 2025. PMID: 40609744 Review.
References
-
- Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. . Cancer 1948;1:634–656.
-
- Bradburn N “Respondent burden.” Proceedings of the Survey Research Methods Section of the American Statistical Association Alexandria, VA, USA: American Statistical Association, 1978 1978;35:40.
Publication types
MeSH terms
Grants and funding
- U10 HL069294/HL/NHLBI NIH HHS/United States
- K23 HL141445/NH/NIH HHS/United States
- R21 HL140314/HL/NHLBI NIH HHS/United States
- K23 HL141445/HL/NHLBI NIH HHS/United States
- R21-HL140314/HL/NHLBI NIH HHS/United States
- UG1 HL069246/HL/NHLBI NIH HHS/United States
- R01 HL166339/NH/NIH HHS/United States
- 27398C0011/ES/NIEHS NIH HHS/United States
- 27305C0011/ES/NIEHS NIH HHS/United States
- U24 CA076518/CA/NCI NIH HHS/United States
- U24 HL138660/HL/NHLBI NIH HHS/United States
- R01 HL166339/HL/NHLBI NIH HHS/United States
- 27307C0011/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous